BPC-157 Dosage: What Human Studies Actually Tested
There is no established BPC-157 dose. See the amounts used in human studies, why the common 250-500 mcg figure is untested, side effects and FDA status in 2026.
Separating human study amounts, animal research and online injection protocols.
There is no established BPC-157 dosage for people. The few human studies used very different routes and amounts: 10 mg injected into the bladder wall, 2 to 4 mg injected into the knee, 10 mg and 20 mg IV infusions in two people, and rectal enemas of 80 mg daily or up to 2 mg/kg. None of them tested the 250 to 500 microgram (mcg) under-the-skin injections that dominate online protocols. FDA found no information to assess how BPC-157 is absorbed or cleared in humans, and a 2026 systematic review rated the human evidence as very low certainty.
Key takeaways
- No approved or recommended dose: BPC-157 is not an FDA-approved drug for any use, so no dose has been established by regulatory review.
- Human studies are few and small: FDA's 2026 review summarized a handful of small human studies, with doses ranging from rectal enemas to single milligram injections into a knee or bladder.
- The online dose has no human trial behind it: The commonly quoted 250 to 500 mcg subcutaneous amount has not been established by a published human dose-finding trial. Animal experiments and proposed compounded product strengths cannot validate it as a human regimen.
- Route matters and is mostly untested: No human study of BPC-157 injected under the skin, or given by mouth, nose spray or skin cream, has published results.
- Vial math is not a dose: A 5 mg or 10 mg vial label tells you what the product claims to contain, not what amount is safe or effective.
BPC-157 Human Study Dosage Chart (Not a Dosing Guide)
| Study | Route and amount | People | What it reported |
|---|---|---|---|
| Veljaca et al., 2002 and 2003 (meeting abstracts) | Rectal enema, 0.25, 0.5, 1 or 2 mg/kg; one dose, then seven daily doses after a one-week washout | 32 healthy volunteers randomized; 24 received BPC-157 | Placebo-controlled; headache and flatulence were reported at similar rates to placebo. The abstracts do not establish reliable human blood levels or pharmacokinetic parameters |
| Ruenzi et al., 2005 (meeting abstract) | Rectal enema, 80 mg once daily for 2 weeks | 53 adults with ulcerative colitis randomized; about 26 assigned BPC-157; 46 completed | Placebo-controlled; difference from placebo not statistically conclusive; reported only as a meeting abstract |
| Lee and Padgett, 2021 | Knee joint injection, 2 to 4 mg, one or two doses | 17 treated, 16 reached by phone (12 given BPC-157 alone) | Retrospective chart review; patients recalled pain relief, no standardized measures |
| Lee et al., 2024 | Intravesical (into the bladder wall) injection, 1 mg at each of 10 sites, 10 mg total in one procedure | 12 women with interstitial cystitis | Uncontrolled pilot; patients reported symptom relief, no adverse events reported |
| Lee and Burgess, 2025 | IV infusion, 10 mg on day 1 and 20 mg on day 2 | 2 healthy adults | Safety pilot; no changes in the blood tests measured, no side effects reported |
Sources: FDA's BPC-157 evaluation for the July 2026 Pharmacy Compounding Advisory Committee, Lee and Padgett, 2021, Lee et al., 2024 and Lee and Burgess, 2025. These are historical research exposures, not a dosing chart for use.
What is BPC-157?
BPC-157 (body protection compound 157, also called bepecin or PL-14736) is a synthetic peptide of 15 amino acids. It was derived from a protein found in human gastric juice and has been studied mainly in rats by research groups in Croatia since the early 1990s, where it was reported to speed the healing of the gut, tendons, ligaments and muscle. FDA noted in 2026 that its molecular targets have not been identified and its mechanism of action remains poorly understood.
Is there a recommended BPC-157 dose?
No. A recommended dose comes from human studies that show which amount helps and which amounts cause harm, followed by regulatory review. BPC-157 has never completed that process. FDA's 2026 evaluation described the human studies as "of short duration," with "small sample sizes," doses "likely exploratory in nature," and limited safety information. An October 2026 systematic review found three eligible human studies with 30 participants in total, judged all three to be of poor methodological quality, and concluded that BPC-157 "should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials" (Poolton et al., Acta Orthopaedica Belgica, 2026).
The amounts in the table above are what researchers or clinicians gave, not amounts shown to be effective or safe. Any figure presented online as "the" BPC-157 dose is a convention from sellers, clinics and user communities.
What did the human studies of BPC-157 find?
The largest reported placebo-controlled BPC-157 study was a 2005 trial of BPC-157 enemas in 53 adults with mild to moderate ulcerative colitis. An earlier placebo-controlled phase 1 study also tested rectal BPC-157 in healthy volunteers. Both are known only through meeting abstracts rather than full published trial reports. The 2005 abstract reported a greater numerical improvement in disease activity with BPC-157 than with placebo, but the estimated difference between groups was not statistically conclusive. FDA found the reporting, including unclear inclusion criteria and endpoint definitions, insufficient to establish effectiveness or safety for ulcerative colitis. A registered phase 1 trial in Mexico planned to test oral tablets of 1, 3 and 6 mg, and 3 mg every 8 hours for two weeks, in about 42 healthy volunteers, but no results have been posted (NCT02637284).
The three more recent reports all come from private clinics in Florida. In the knee study, 11 of 12 patients who had received BPC-157 alone said their pain improved when contacted by phone six months to a year later. In the bladder study, 10 of 12 women said their symptoms fully resolved. In the IV study, two people received infusions without changes in the heart, liver, kidney, thyroid or blood-sugar markers that were tested. None of these studies had a control group, and the systematic review rated their combined certainty as very low because of serious risk of bias, indirectness and imprecision.
Where does the 250 to 500 mcg BPC-157 dose come from?
It does not come from a human trial. Most BPC-157 research in animals uses weight-based amounts in micrograms or even nanograms per kilogram. For example, a rat ligament study gave 10 mcg/kg or 10 ng/kg once daily into the abdominal cavity, a cream containing 1 mcg per gram, or BPC-157 in drinking water (Cerovecki et al., Journal of Orthopaedic Research, 2010). Intraperitoneal (into the abdominal cavity) dosing in rats is not evidence for injection under the skin in people. These animal exposures differ in route, body-weight scaling and study design from the fixed amounts commonly repeated online. They cannot establish a safe or effective subcutaneous dose in humans, and these studies do not document where the online 250 to 500 mcg convention came from.
Proposed compounded products used similar strengths. Pharmacy nominations reviewed by FDA proposed oral capsules of 250 mcg, 500 mcg and 1 mg, an injection of 2,000 mcg per milliliter under the skin, a nasal spray of 50 mcg per spray and a 1 mg rectal suppository. FDA treated these as proposed product strengths. It found no human studies in its review that gave BPC-157 by mouth, under the skin, in the nose or through the skin, and no repeat-dose animal toxicity studies by those routes.
Oral vs injectable vs nasal BPC-157
| Route | Human evidence |
|---|---|
| Subcutaneous (under the skin) injection | No published human studies |
| Oral capsule or tablet | One registered phase 1 trial with no posted results |
| Nasal spray | No published human studies |
| Topical or transdermal | No published human studies |
| Rectal enema | One placebo-controlled phase 1 study in healthy volunteers, reported in two meeting abstracts, and one placebo-controlled ulcerative colitis trial reported as a meeting abstract |
| Joint, bladder or IV injection | Three small uncontrolled reports from private clinics (30 people combined) |
In animals, BPC-157 given by IV was cleared quickly, with a half-life of about 5 minutes in dogs and 15 minutes in rats. FDA found no information to assess its pharmacokinetics in humans by any route, so this cannot tell you how long BPC-157 lasts or how often it would need to be given in humans.
What are the side effects of BPC-157?
The small human studies reported few side effects: headache and flatulence with enemas, at rates similar to placebo, and no adverse events in the knee, bladder or IV reports. FDA cautioned that these studies were short, small and unclear about safety monitoring, so they cannot show that BPC-157 is safe.
In the 2005 ulcerative colitis trial, three participants in the BPC-157 group and two in the placebo group withdrew because of adverse events, described mainly as progression of the underlying disease. The short abstract does not establish whether BPC-157 caused these events.
FDA's search of its adverse event reporting system found three reports, all involving injected BPC-157. One person had nine days of redness and swelling at the injection site while also injecting compounded thymosin. One had shortness of breath leading to an emergency room visit. One person injecting a BPC-157 and TB-500 product labeled "for research purposes only" developed darkening of the skin and gums, and the same reaction returned when the product was used again. FDA said it is unclear whether these events were caused by BPC-157.
FDA also raised concerns that human data cannot yet answer. It could not rule out immune reactions (immunogenicity) to injected BPC-157 because of possible peptide clumping and impurities. In 28-day muscle-injection studies in rats and dogs, BPC-157 was linked to changes in blood clotting times and liver-related blood markers, and no longer-term studies were available. FDA did not identify carcinogenicity studies in its 2026 assessment.
Seek emergency care right away for signs of a severe allergic reaction (anaphylaxis), such as trouble breathing, swelling of the face, lips or throat, widespread hives, or fainting (MedlinePlus: anaphylaxis). Redness that spreads, warmth, pain or fever around an injection site can signal a skin infection and needs medical attention (MedlinePlus: cellulitis). Problems with a compounded product can be reported to FDA MedWatch.
Does BPC-157's FDA status set a dose?
No. BPC-157 is not FDA-approved for any human use. In their May 2026 evaluation for the advisory committee, FDA staff proposed not adding BPC-157 free base or BPC-157 acetate to the 503A Bulks List, citing poor characterization, missing safety and immunogenicity data and insufficient evidence of effectiveness for ulcerative colitis. On July 23, 2026, the Pharmacy Compounding Advisory Committee nevertheless voted 8 to 6, with one abstention, to recommend adding both forms (FDA meeting page). The vote is advisory.
On October 30, 2026, HHS published notice of an interim enforcement-discretion policy for certain peptides used in 503A compounding (Federal Register notice 2026-22192). BPC-157 appears in Appendix A of the HHS 503A peptide enforcement-discretion policy, including Appendix B, while Appendix B specifically addresses BPC-157 acetate in subcutaneous, intramuscular, oral and topical dosage forms. The policy describes conditions for limited compounding, including patient-specific prescriptions, a single active pharmaceutical ingredient, identity and quality documentation, and evidence of adequate human bioavailability for oral formulations. It does not establish a clinically validated dose or grant FDA drug approval. For the full regulatory timeline, see our BPC-157 FDA approval status guide.
BPC-157 is also prohibited at all times in tested sport under the World Anti-Doping Agency's S0 category for non-approved substances (WADA Prohibited List).
How to read a BPC-157 vial label
Research suppliers sell BPC-157 in vials labeled by total peptide content, most often 5 mg or 10 mg. One milligram equals 1,000 micrograms, so a 5 mg vial is labeled as containing 5,000 mcg. That figure is a claimed product quantity, not a clinically validated dose or proof of the vial's identity, purity or potency. FDA noted that BPC-157 has no standardized official name and that it has encountered multiple salts and derivatives sold under the same common name, so a buyer may receive a different substance than the label implies.
For concentration arithmetic, see our BPC-157 dosage calculator, and for storage after mixing, see how long BPC-157 lasts in the fridge. Those tools describe what a vial contains; they are not dosing instructions and do not make any route safe. BPC-157 is also sold blended with TB-500, covered in our Wolverine Stack dosage guide and TB-500 dosage chart.
Frequently asked questions
How much BPC-157 should I take?
There is no established safe and effective BPC-157 dose for human use. Human studies gave milligram amounts injected into a knee or the bladder wall, two IV infusions to two people, and rectal enemas, but none of them established a regimen. BPC-157 is not an FDA-approved treatment.
Is BPC-157 dosed in mcg or mg?
Both units appear. Vials are labeled in milligrams, while online protocols quote micrograms. The human studies used milligram amounts by routes other than subcutaneous injection. Neither unit corresponds to a tested subcutaneous dose.
Is there a BPC-157 nasal spray dosage?
No human study has tested nasal BPC-157. A pharmacy nomination proposed a 50 mcg-per-spray product, but FDA found no human data for that route.
How long does BPC-157 stay in your system?
Unknown in humans. In dogs and rats, IV BPC-157 had a half-life of roughly 5 to 15 minutes, but FDA found no human data on how long it lasts by any route.
About this article: PeptideStack is an affiliate-supported research publisher. The Peptide Partners card on this page is a paid referral offer and is not medical guidance. This article summarises published BPC-157 research and FDA assessments; it does not recommend purchasing or using BPC-157. The doses described are historical research exposures, not instructions for human use. For treatment decisions, consult a licensed healthcare professional.
You Might Also Like

BPC-157 FDA Approval Status 2026: Clinical Trials
Is BPC-157 FDA approved in 2026? See the latest compounding review, FDA docket updates, and what researchers need to know.

Wolverine Stack Dosage: BPC-157 + TB-500 Blend Guide
Wolverine Stack dosage reference: BPC-157 + TB-500 blend ratios, reconstitution math, syringe-unit charts, cycle conventions, and evidence limits.

How Long Can You Store BPC 157? Storage Guide
How long can you store BPC 157? Storage guide for lyophilized powder, reconstituted vials, fridge timing, freezing, and discard signs.

